Zimmer Biomet stock falls after leadership moves and guidance reiteration

Zimmer Biomet Holdings Inc. stock (ISIN US98956P1021) traded at about USD 94.22 on the New York Stock Exchange on September 8, 2026, down 3.9 percent from the prior close, leaving the shares roughly mid-range between a 52-week low of USD 79.12 and a 52-week high of USD 106.88.

Stock reacts to guidance and sector headwinds

According to GuruFocus on September 8, 2026, Zimmer Biomet shares fell 3.9 percent to USD 94.22, while the portal cites a 52-week price range of USD 79.12 to USD 106.88 and a calculated intrinsic GF Value of USD 124.90, implying the stock is about 24.6 percent below that estimate.

A sector ripple also weighed on sentiment: as MSN reported on September 8, 2026, rival Stryker hit a new 52-week low after discussing headwinds in its vascular and orthopedics segments at the 2026 Wells Fargo Healthcare Conference, and the weakness pulled Zimmer Biomet shares lower as well.

Q2 2026 results and raised full-year guidance

Zimmer Biomet’s fundamental backdrop is anchored by its second-quarter 2026 results and updated outlook. As Zacks noted on September 9, 2026, Zimmer Biomet posted adjusted earnings per share of USD 2.07 for Q2 2026, beating the Zacks consensus estimate of USD 2.01 by about 3 percent.

In the same overview, Zacks reports that Zimmer Biomet raised its 2026 revenue guidance after Q2: reported revenue growth is now expected in a range of 3.9 to 4.9 percent, up from a prior projection of 2.5 to 4.5 percent, while constant-currency revenue growth is projected between 3.4 and 4.4 percent compared with the earlier 2 to 4 percent range.

Organic constant-currency growth is now forecast between 2.25 and 3.25 percent versus the previous 1 to 3 percent band, showing management’s slightly more optimistic view of the underlying momentum, according to Zacks.

For the full year 2026, Zimmer Biomet now expects adjusted earnings in a range of USD 8.47 to USD 8.59 per share, modestly above the prior guidance of USD 8.40 to USD 8.55 per share, a move that effectively adds up to USD 0.19 at the top end of the range compared with the previous low end, as outlined by Zacks.

Leadership changes and reiterated outlook

The company has also moved to adjust its organizational structure in the Americas. On September 8, 2026, Zimmer Biomet announced several leadership promotions intended to streamline its Americas and Global Business Group organizations and accelerate commercial transformation, according to a press release highlighted by InvestingNews.

A separate article on Zimmer Biomet from ChoiceStockUS on September 9, 2026 notes that the company reiterated the annual financial outlook it originally presented on August 5, 2026 despite the leadership reorganization, underlining management’s confidence in reaching the 2026 targets.

That same overview from ChoiceStockUS cites sell-side consensus estimates pointing to revenue of USD 8,596.18 million in 2026, up about 4.43 percent year on year, rising to USD 8,904.70 million in 2027 and USD 9,253.50 million in 2028, alongside expected earnings per share of USD 4.86 in 2026, USD 5.60 in 2027 and USD 6.25 in 2028.

Valuation, risks and investor takeaways

From a valuation perspective, GuruFocus assigns Zimmer Biomet a GF Score of 72 out of 100 and concludes that, at USD 94.22 versus a GF Value estimate of USD 124.90, the stock trades at a discount with a margin of safety of about 24.6 percent.

However, risks around orthopedics demand and procedure volumes remain visible. The report on Stryker’s comments about headwinds in vascular and orthopedics, which pressured Zimmer Biomet’s share price on September 8, 2026, suggests that investor sentiment toward the broader orthopedics segment can shift quickly when peers flag challenges, as described by MSN.

Operationally, Zimmer Biomet also faces restructuring pressure in parts of its manufacturing footprint: a report from MarketScreener on September 9, 2026 indicates that up to 580 jobs could be cut at the company’s Winterthur production unit in Switzerland, out of a total of about 730 positions there, underscoring the scale of cost adjustments under way.

Despite these risks, consensus figures compiled by ChoiceStockUS still point to steady top-line growth of roughly 3.6 to 3.9 percent per year in 2027 and 2028 and double-digit annual EPS increases from 2026 through 2028, suggesting that profitability improvements and portfolio mix shifts are central to the medium-term equity story.

Zimmer Biomet stock price snapshot

Zimmer Biomet stock most recently closed at about USD 94.22 on the New York Stock Exchange on September 8, 2026, with the shares trading between USD 79.12 and USD 106.88 over the past 52 weeks, placing the current level closer to the middle of that range than to either extreme. Based on this price, the company’s equity market capitalization is in the multi-billion-dollar range in United States dollars as of early September 2026.

More news and analyses on Zimmer Biomet stock